Azeria Therapeutics
Latest round
- Series B
Last raised
- Nov 2019
Total raised
- $14M
Investors
- 2
About Azeria Therapeutics
Founded in 2017 in Cambridge, UK, Azeria Therapeutics Limited specializes in creating therapeutic solutions for rare genetic conditions.Azeria Therapeutics Limited focuses on developing novel therapies for rare diseases, addressing unmet medical needs through proprietary drug discovery and development processes.In the near future, Azeria Therapeutics Limited plans to launch new therapeutic products aimed at treating rare genetic disorders, with strategic timelines for market entry based on research progress.
Who invested in Azeria Therapeutics
2 investors across 2 rounds
See all investors in Azeria Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Azeria Therapeutics
Who invested in Azeria Therapeutics?
Azeria Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Azeria Therapeutics raised?
Azeria Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Azeria Therapeutics last raise money?
Azeria Therapeutics's most recent round on record is a Series B, in Nov 2019.
What does Azeria Therapeutics do?
Founded in 2017 in Cambridge, UK, Azeria Therapeutics Limited specializes in creating therapeutic solutions for rare genetic conditions.
Where is Azeria Therapeutics headquartered?
Azeria Therapeutics is headquartered in Cambridge, UK.
Which VCs invest in companies like Azeria Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Azeria Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Azeria Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.